These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39312187)

  • 1. Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.
    Habibollahi P; Gurevich A; Hui JZ; Weinfurtner K; McClung G; Adler J; Soulen MC; Kaplan DE; Nadolski GJ; Hunt SJ; Tsourkas A; Gade TP
    Mol Cancer Ther; 2024 Dec; 23(12):1815-1826. PubMed ID: 39312187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
    Bi Y; Jiang H; Wang P; Song B; Wang H; Kong X; Li Z
    Oncotarget; 2017 Aug; 8(32):52866-52876. PubMed ID: 28881778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma.
    Yu L; Yang X; Huang N; Lang QL; He QL; Jian-Hua W; Liang-Peng G
    Cancer Biol Ther; 2020 Jul; 21(7):597-603. PubMed ID: 32240054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
    Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
    Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
    Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
    Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.
    Szoor A; Vaidya A; Velasquez MP; Mei Z; Galvan DL; Torres D; Gee A; Heczey A; Gottschalk S
    Mol Ther Oncolytics; 2017 Sep; 6():69-79. PubMed ID: 28856237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics.
    Mu W; Jiang D; Mu S; Liang S; Liu Y; Zhang N
    ACS Appl Mater Interfaces; 2019 Jul; 11(26):23591-23604. PubMed ID: 31179679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
    Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
    Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
    Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
    BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
    Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
    Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.